LSNME/SW1
An experimental COVID-19 mRNA/exosome vaccine.
General information
LSNME/SW1 is an experimental COVID-19 vaccine formulation based on exosomes derived from the 293F cell line, which are loaded with mRNA encoding SARS-CoV-2 Spike protein and mRNA encoding a fusion protein of SARS-CoV-2 Nucleocapsid, Spike fragments, Membrane, and Envelope proteins and the human Lamp1 protein (Tsai et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
Spike protein Envelope protein Nucleocapsid protein Membrane protein Cell-based therapy Animal model In vitro Mixed substance Extracellular vesicles |
293F cells; C57BL/6J mice | 5.16 | mRNA-loaded in exosomes derived from 293F cells were injected intramuscularly in mice. The formulation elicited humoral and cellular (CD4+ and CD8+) immune responses to both Spike and Nucleocapsid proteins. The Spike-reactive T-cell response was Th-1 biased. The formulation was not toxic and did not induce adverse reactions in mice. |
Oct/01/2021 |
|
Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
Spike protein RNA Envelope protein Nucleocapsid protein Membrane protein Cell-based therapy Animal model In vitro Mixed substance Extracellular vesicles |
293F cells; C57BL/6J mice | 5.16 | mRNA-loaded in exosomes derived from 293F cells were injected intramuscularly in mice. The formulation elicited humoral and cellular (CD4+ and CD8+) immune responses to both Spike and Nucleocapsid proteins. The Spike-reactive T-cell response was Th-1 biased. The formulation was not toxic and did not induce adverse reactions in mice. |
Oct/01/2021 |
